A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122
Last updated 2026-05-01
Summary
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.
Conditions
- Advanced Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Small Cell Carcinoma
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Stage III Breast Cancer AJCC v7
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage III Lung Small Cell Carcinoma AJCC v7
- Stage III Pancreatic Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Small Cell Carcinoma AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Small Cell Carcinoma AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- Stage IV Lung Small Cell Carcinoma AJCC v7
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma
- Unresectable Lung Small Cell Carcinoma
- Unresectable Pancreatic Adenocarcinoma
- Unresectable Pancreatic Carcinoma
- Unresectable Triple-Negative Breast Carcinoma
Interventions
- OTHER
-
18F-Fluoromisonidazole
Correlative studies
- DRUG
-
Cediranib Maleate
Given PO
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- DRUG
-
Given PO
- PROCEDURE
-
Positron Emission Tomography
Correlative studies
Sponsors & Collaborators
- collaborator INDUSTRY
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Joseph W Kim · Yale University Cancer Center LAO
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-31
- Primary Completion
- 2022-06-22
- Completion
- 2027-04-10
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
NCT03991832 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
NCT02588105 ·Status: COMPLETED ·Phase: PHASE1
-
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
NCT01894256 ·Status: COMPLETED ·Phase: PHASE1
-
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
NCT02511795 ·Status: COMPLETED ·Phase: PHASE1
-
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
NCT02430311 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
NCT01832857 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
NCT02884128 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
NCT03205176 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
NCT05181865 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
NCT04514497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
NCT01894243 ·Status: COMPLETED ·Phase: PHASE1
-
OLAParib COmbinations
NCT02576444 ·Status: TERMINATED ·Phase: PHASE2
-
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
NCT04197713 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Trial of TB511 in Advanced Solid Tumors
NCT06400160 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387 ·Status: COMPLETED ·Phase: PHASE1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
NCT02740985 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924 ·Status: RECRUITING ·Phase: PHASE1/PHASE2